These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 23754735)

  • 1. Population pharmacokinetics of JNJ-37822681, a selective fast-dissociating dopamine D₂-receptor antagonist, in healthy subjects and subjects with schizophrenia and dose selection based on simulated D₂-receptor occupancy.
    Hoeben E; Neyens M; Mannaert E; Schmidt M; Vermeulen A
    Clin Pharmacokinet; 2013 Nov; 52(11):1005-15. PubMed ID: 23754735
    [TBL] [Abstract][Full Text] [Related]  

  • 2. D₂-receptor occupancy measurement of JNJ-37822681, a novel fast off-rate D₂-receptor antagonist, in healthy subjects using positron emission tomography: single dose versus steady state and dose selection.
    Schmidt ME; de Boer P; Andrews R; Neyens M; Rossenu S; William Falteos D; Mannaert E
    Psychopharmacology (Berl); 2012 Dec; 224(4):549-57. PubMed ID: 22773165
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In vivo quantification of striatal dopamine D2 receptor occupancy by JNJ-37822681 using [11C]raclopride and positron emission tomography.
    te Beek ET; de Boer P; Moerland M; Schmidt ME; Hoetjes NJ; Windhorst AD; van Berckel BN; Cohen AF; van Gerven JM; Lammertsma AA
    J Psychopharmacol; 2012 Aug; 26(8):1128-35. PubMed ID: 22290934
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetic Evaluation of Blonanserin Transdermal Patch: Population Analysis and Simulation of Plasma Concentration and Dopamine D
    Kitamura A; Takagaki T; Nemoto D; Tomita Y; Nishibe H; Kakuyama H
    J Clin Pharmacol; 2021 Aug; 61(8):1069-1080. PubMed ID: 33599975
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Differential responses to JNJ-37822681, a specific and fast dissociating dopamine D2 receptor antagonist, in cynomolgus monkey and Sprague-Dawley rat general toxicology studies: clinical observations, prolactin levels, mammary histopathology findings and toxicokinetics.
    de Waal EJ; Desmidt M; Korte S; Niehoff M; Chase K; Arrowsmith W; Lampo A
    J Appl Toxicol; 2014 Sep; 34(9):974-92. PubMed ID: 24105799
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacology of JNJ-37822681, a specific and fast-dissociating D2 antagonist for the treatment of schizophrenia.
    Langlois X; Megens A; Lavreysen H; Atack J; Cik M; te Riele P; Peeters L; Wouters R; Vermeire J; Hendrickx H; Macdonald G; De Bruyn M
    J Pharmacol Exp Ther; 2012 Jul; 342(1):91-105. PubMed ID: 22490380
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The use of healthy volunteers instead of patients to inform drug dosing studies: a [¹¹C]raclopride PET study.
    Kim E; Howes OD; Kim BH; Yu KS; Jeong JM; Lee JS; Kim SJ; Jang IJ; Park JS; Kim YG; Shin SG; Turkheimer FE; Kapur S; Kwon JS
    Psychopharmacology (Berl); 2011 Oct; 217(4):515-23. PubMed ID: 21503604
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A double-blind, randomized, placebo-controlled study with JNJ-37822681, a novel, highly selective, fast dissociating D₂ receptor antagonist in the treatment of acute exacerbation of schizophrenia.
    Schmidt ME; Kent JM; Daly E; Janssens L; Van Osselaer N; Hüsken G; Anghelescu IG; Van Nueten L
    Eur Neuropsychopharmacol; 2012 Oct; 22(10):721-33. PubMed ID: 22464973
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Striatal Dopamine D2 Receptor Occupancy Induced by Daily Application of Blonanserin Transdermal Patches: Phase II Study in Japanese Patients With Schizophrenia.
    Nishibe H; Tateno A; Sakayori T; Yamamoto M; Kim W; Kakuyama H; Okubo Y
    Int J Neuropsychopharmacol; 2021 Feb; 24(2):108-117. PubMed ID: 32936897
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Striatal and extrastriatal dopamine D2 receptor occupancy by a novel antipsychotic, blonanserin: a PET study with [11C]raclopride and [11C]FLB 457 in schizophrenia.
    Tateno A; Arakawa R; Okumura M; Fukuta H; Honjo K; Ishihara K; Nakamura H; Kumita S; Okubo Y
    J Clin Psychopharmacol; 2013 Apr; 33(2):162-9. PubMed ID: 23422369
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Does early improvement predict response to the fast-dissociating D₂ receptor antagonist JNJ-37822681 in patients with acute schizophrenia?
    Anghelescu IG; Janssens L; Kent J; de Boer P; Tritsmans L; Daly EJ; van Nueten L; Schmidt ME
    Eur Neuropsychopharmacol; 2013 Sep; 23(9):1043-50. PubMed ID: 22995972
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Development of a population pharmacokinetic model to predict brain distribution and dopamine D2 receptor occupancy of raclopride in non-anesthetized rat.
    Wong YC; Ilkova T; van Wijk RC; Hartman R; de Lange ECM
    Eur J Pharm Sci; 2018 Jan; 111():514-525. PubMed ID: 29106979
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Population pharmacokinetics and prediction of dopamine D2 receptor occupancy after multiple doses of RBP-7000, a new sustained-release formulation of risperidone, in schizophrenia patients on stable oral risperidone treatment.
    Laffont CM; Gomeni R; Zheng B; Heidbreder C; Fudala PJ; Nasser AF
    Clin Pharmacokinet; 2014 Jun; 53(6):533-43. PubMed ID: 24464285
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dopamine D2/3 Receptor Occupancy Following Dose Reduction Is Predictable With Minimal Plasma Antipsychotic Concentrations: An Open-Label Clinical Trial.
    Nakajima S; Uchida H; Bies RR; Caravaggio F; Suzuki T; Plitman E; Mar W; Gerretsen P; Pollock BG; Mulsant BH; Mamo DC; Graff-Guerrero A
    Schizophr Bull; 2016 Jan; 42(1):212-9. PubMed ID: 26221049
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Contribution of SPECT measurements of D2 and 5-HT2A occupancy to the clinical development of the antipsychotic SB-773812.
    Catafau AM; Bullich S; Nucci G; Burgess C; Gray F; Merlo-Pich E;
    J Nucl Med; 2011 Apr; 52(4):526-34. PubMed ID: 21421726
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dopamine D₂/₃ occupancy of ziprasidone across a day: a within-subject PET study.
    Suzuki T; Graff-Guerrero A; Uchida H; Remington G; Caravaggio F; Borlido C; Pollock B; Mulsant B; Deluca V; Ismail Z; Mamo D
    Psychopharmacology (Berl); 2013 Jul; 228(1):43-51. PubMed ID: 23417515
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Metabolic and body mass parameters after treatment with JNJ-37822681, a novel fast-dissociating D2 receptor antagonist, vs olanzapine in patients with schizophrenia.
    Daly EJ; Kent JM; Janssens L; Newcomer JW; Hüsken G; De Boer P; Tritsmans L; Schmidt ME
    Ann Clin Psychiatry; 2013 Aug; 25(3):173-83. PubMed ID: 23926573
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dopamine D2 receptor occupancy by perospirone: a positron emission tomography study in patients with schizophrenia and healthy subjects.
    Arakawa R; Ito H; Takano A; Okumura M; Takahashi H; Takano H; Okubo Y; Suhara T
    Psychopharmacology (Berl); 2010 May; 209(4):285-90. PubMed ID: 20349050
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Exploration of optimal dosing regimens of haloperidol, a D2 Antagonist, via modeling and simulation analysis in a D2 receptor occupancy study.
    Lim HS; Kim SJ; Noh YH; Lee BC; Jin SJ; Park HS; Kim S; Jang IJ; Kim SE
    Pharm Res; 2013 Mar; 30(3):683-93. PubMed ID: 23138261
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A positron emission tomography study of quetiapine in schizophrenia: a preliminary finding of an antipsychotic effect with only transiently high dopamine D2 receptor occupancy.
    Kapur S; Zipursky R; Jones C; Shammi CS; Remington G; Seeman P
    Arch Gen Psychiatry; 2000 Jun; 57(6):553-9. PubMed ID: 10839333
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.